Navigation Links
Tobira's Next-Generation Once-Daily CCR5 Receptor Antagonist Demonstrates Efficacy, Safety and Tolerability in Treatment-Experienced Patients With HIV
Date:2/17/2010

SAN FRANCISCO, Feb. 17 /PRNewswire/ -- The first-ever-reported Phase II data for TBR-652, which is being developed by Tobira Therapeutics for the treatment of HIV infection, demonstrate that the CCR5 receptor antagonist provides potent antiviral activity and is generally safe and well-tolerated in its proof of concept trial. The data were released here today in an oral presentation at the 17th Conference on Retroviruses and Opportunistic Infections (CROI).

In a Phase IIa trial involving 54 treatment-experienced HIV infected patients, a 10-day course of once-daily, TBR-652 monotherapy produced a median nadir decline from baseline in HIV viral load of up to 1.8 log10 copies/mL. There were no serious adverse events, deaths or study drug-related discontinuations in the study.  Dose dependent changes in MCP-1 concentrations were also observed, demonstrating TBR-652's dual CCR5/CCR2 mechanism of action and potential anti-inflammatory benefits.  

"These data demonstrate that TBR-652 offers potent viral suppression and excellent safety and tolerability in this short-term study," observed Calvin J. Cohen, M.D., M.Sc., of the Community Research Initiative of New England. "This compound provides the potential for once-daily dosing, without the need for a pharmacologic boosting agent, an important benefit for simplified dosing and ease of administration in early stage disease."

Dr. Cohen presented data from Study 652-2-201, a double-blind, placebo-controlled, dose-escalation trial in which patients were randomized four-to-one to receive doses of TBR-652 of 25mg, 50mg, 75mg, 100mg, 150mg and placebo.  

All patients were HIV treatment-experienced, though none had previously been treated with a CCR5 antagonist. Most adverse events in the study were mild in severity (Grade 1). There were no clin
'/>"/>

SOURCE Tobira Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The Oclaro Next-Generation Orion Fiber-Coupled Diode Laser Raises the Bar for Performance, Cost and Reliability for Solid State Lasers
2. WorldHeart Signs Agreements for Next-Generation Minimally Invasive Blood Pump
3. Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease
4. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
5. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent
6. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
7. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
8. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
9. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
10. ISTA Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Once-Daily XiDay(TM)
11. Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 This report analyzes the ... by the following Product Segments: SPECT Systems (Includes SPECT and ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... estimates and forecasts are provided for the period 2013 through ...
(Date:9/16/2014)... -- Chairman and CEO Bernard J. Tyson announced ... the role of interim chief information officer (CIO) for ... "Kaiser Permanente is a recognized leader ... high-quality care and service we provide to our 9.5 ... extensive experience in information technology. I am confident that ...
(Date:9/16/2014)... 16, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... on licensing, developing and commercializing innovative biopharmaceutical products ... commencing an underwritten registered public offering of shares ... are being offered by Aratana Therapeutics. ... joint book-running managers for the offering.  ...
Breaking Medicine Technology:Global Nuclear Medicine Imaging Equipment Industry 2Global Nuclear Medicine Imaging Equipment Industry 3Global Nuclear Medicine Imaging Equipment Industry 4Global Nuclear Medicine Imaging Equipment Industry 5Global Nuclear Medicine Imaging Equipment Industry 6Global Nuclear Medicine Imaging Equipment Industry 7Global Nuclear Medicine Imaging Equipment Industry 8Global Nuclear Medicine Imaging Equipment Industry 9Global Nuclear Medicine Imaging Equipment Industry 10Global Nuclear Medicine Imaging Equipment Industry 11Global Nuclear Medicine Imaging Equipment Industry 12Global Nuclear Medicine Imaging Equipment Industry 13Global Nuclear Medicine Imaging Equipment Industry 14Global Nuclear Medicine Imaging Equipment Industry 15Global Nuclear Medicine Imaging Equipment Industry 16Global Nuclear Medicine Imaging Equipment Industry 17Global Nuclear Medicine Imaging Equipment Industry 18Global Nuclear Medicine Imaging Equipment Industry 19Global Nuclear Medicine Imaging Equipment Industry 20Global Nuclear Medicine Imaging Equipment Industry 21Global Nuclear Medicine Imaging Equipment Industry 22Global Nuclear Medicine Imaging Equipment Industry 23Global Nuclear Medicine Imaging Equipment Industry 24Global Nuclear Medicine Imaging Equipment Industry 25Global Nuclear Medicine Imaging Equipment Industry 26Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals Name Interim Chief Information Officer 2Aratana Therapeutics, Inc. Announces Proposed Public Offering 2
... LLC, a global leader in,non invasive high intensity ... of the Sonablate(R) International HIFU Registry,(SIHR), along with ... Takai,Hospital Supply Co., Ltd., (THS). The SIHR is ... about prostate cancer treatment using HIFU.,It was established ...
... candidates to ... obesity patients, SAN DIEGO, July 9 Orexigen(R) Therapeutics,Inc. ... randomizing patients,in ZB-202, a second Phase IIb clinical trial for ... trial is designed,to build on highly encouraging safety and efficacy ...
Cached Medicine Technology:Sonablate(R) International HIFU Registry is the First Worldwide HIFU Clinical Registry for Prostate Cancer Treatments 2Sonablate(R) International HIFU Registry is the First Worldwide HIFU Clinical Registry for Prostate Cancer Treatments 3Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule 2Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule 3Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule 4
(Date:9/17/2014)... Calif. (PRWEB) September 17, 2014 ... monthly interruptions, giving girls of all ages an ... wellness company founded by women, for women, announces ... Uninterrupted® (http://GirlU.com) to relieve the symptoms ... bloating and irritability. , As a lifelong ...
(Date:9/17/2014)... 17, 2014 In a new video ... William Groff, an expert on the condition known as PPP, ... penile papules , or PPP, is a condition that affects ... men may be affected as well. The condition is characterized ... , “While PPP is not a sexually transmitted disease and ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 A raucous ... Disease come together to form author Nancy Chovancek’s laughter-filled ... book is a collection of short stories that prove ... on fun. With a positive message of empowerment and ... Chovancek is a proven author with two books under ...
(Date:9/17/2014)... GA (PRWEB) September 17, 2014 ... District (DHCHD) has implemented its CollaborNet™ Health ... exchange of patients’ health information between Coon Memorial ... Texas, and physicians in the community. , ... application to enable electronic referrals by physicians to ...
(Date:9/17/2014)... Seattle, Wa (PRWEB) September 17, 2014 ... published by the Telegraph in August 2014, scientists made ... cure for diabetes, but still failed. The article indicates ... , Despite this existing fact, there are many forward-thinking ... for diabetes treatment in a natural way. Dr. Kenneth ...
Breaking Medicine News(10 mins):Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 2Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 3Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 4Health News:New Video Depicts Best Treatment for PPP 2Health News:New Video Depicts Best Treatment for PPP 3Health News:Dallam-Hartley Counties Hospital District Deploys Holon's Health Information Exchange (HIE) Solution to Facilitate Improved Patient Care 2Health News:Dallam-Hartley Counties Hospital District Deploys Holon's Health Information Exchange (HIE) Solution to Facilitate Improved Patient Care 3Health News:Discover a Safe and Effective Treatment for Diabetes with The Diabetes Protocol – Vinamy 2
... 5 seek any assistance, MORAGA, Calif., Oct. 9 ... common disorders, it is regularly under diagnosed by,medical professionals., ... -- muscle tension,headache, nausea, fatigue, or trembling -- before ... during times of stress such as a,divorce, job change ...
... Results of a multicenter study led by Johns Hopkins ... babies with hydrocortisone, a steroid believed to fight inflammation ... treatment offers little or no benefit and that low ... levels, on the other hand, appeared to increase the ...
... New Report Shows Only 17% of Employers Offer Vision Benefits, ... have taken center stage in the upcoming election, worries about,the ... minds of most,Americans. For the 120 million Americans with vision ... value on maintaining healthy vision,the lack of vision coverage is ...
... Generations agrees to sell patents to Life Spine, ... firm Life Spine, Inc. announced today that it has ... LLC. Terms of,the transaction were not disclosed., According ... property expansion is critical. "The core of the spine ...
... Oct. 8 The Hain Celestial,Group, Inc. (Nasdaq: ... food and personal,care products company, today announced that ... to make a presentation regarding the,Company on Wednesday, ... Natural Boston Conference., (Logo: http://www.newscom.com/cgi-bin/prnh/20050324/NYTH131 ...
... Predictive medicine company,PreMD Inc. (TSX: PMD; PREMF.pk) ... has completed its previously announced debenture financing ... Midsummer,Investment, Ltd. The gross proceeds of the ... general corporate purposes., "We are very ...
Cached Medicine News:Health News:40 Million Americans Endure Anxiety Everyday 2Health News:Steroid treatment offers no benefit in preemies, Hopkins Children's study suggests 2Health News:Steroid treatment offers no benefit in preemies, Hopkins Children's study suggests 3Health News:Americans Place High Value on Eyesight, Yet Many Still Lack Vision Coverage 2Health News:Americans Place High Value on Eyesight, Yet Many Still Lack Vision Coverage 3Health News:Hain Celestial to Present at Canaccord Adams Healthy Living Naturally Boston Conference on October 15, 2008 2Health News:PreMD Inc. Completes Secured Debenture Financing 2
Cholesterol FS. For determination of cholesterol in serum or plasma. Available with Calibrator: Trucal U and Controls: Trulab N, Trulab P Trulab L....
Intended for the quantitative determination of total cholesterol in serum. Single vial, dry powder reagent. Reaction: Endpoint. Wavelength: 500 nm. Linearity: 700 mg/dL (12.9 mmol/L)....
This true 8-bit integrated and cooled imaging system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lightin...
... range of Platelet aggregometers allows to ... particular needs. Single, dual and four ... recorder outputs or digital computer outputs. ... aggregometers, which measure platelet aggregation in ...
Medicine Products: